80 related articles for article (PubMed ID: 15143295)
1. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.
Golledge J; McCann M; Mangan S; Lam A; Karan M
Stroke; 2004 Jul; 35(7):1636-41. PubMed ID: 15143295
[TBL] [Abstract][Full Text] [Related]
2. The role of the osteoprotegerin/RANKL/RANK axis and osteopontin in acute coronary syndrome.
Vega-Rosales JA; Saucedo-Orozco H; Márquez-Velasco R; Cruz-Soto R; Zazueta-Salido DF; Koretzky SG; Salinas-Arteaga G; Guarner-Lans V; Pech-Manzano L; Pérez-Torres I; Tavera-Alonso C; Soto ME
Arch Cardiol Mex; 2024 May; ():. PubMed ID: 38810225
[TBL] [Abstract][Full Text] [Related]
3. Reliability, stability during long-term storage, and intra-individual variation of circulating levels of osteopontin, osteoprotegerin, vascular endothelial growth factor-A, and interleukin-17A.
Nakamizo T; Cologne J; Kishi T; Takahashi T; Inoue M; Ryukaku H; Hayashi T; Kusunoki Y; Fujiwara S; Ohishi W
Eur J Med Res; 2024 Feb; 29(1):133. PubMed ID: 38368424
[TBL] [Abstract][Full Text] [Related]
4. Relationships between Osteopontin, Osteoprotegerin, and Other Extracellular Matrix Proteins in Calcifying Arteries.
Kuzan A; Chwiłkowska A; Maksymowicz K; Abramczyk U; Gamian A
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672202
[TBL] [Abstract][Full Text] [Related]
5. The Role of Osteopontin in Atherosclerosis and Its Clinical Manifestations (Atherosclerotic Cardiovascular Diseases)-A Narrative Review.
Kadoglou NPE; Khattab E; Velidakis N; Gkougkoudi E
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137398
[TBL] [Abstract][Full Text] [Related]
6. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods.
Basiak M; Hachula M; Kosowski M; Machnik G; Maliglowka M; Dziubinska-Basiak M; Krysiak R; Okopien B
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570897
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential drug targets for vascular dementia and carotid plaques by analyzing underlying molecular signatures shared by them.
Shu J; Ren Y; Tan W; Wei W; Zhang L; Chang J
Front Aging Neurosci; 2022; 14():967146. PubMed ID: 36262886
[TBL] [Abstract][Full Text] [Related]
8. Identification Markers of Carotid Vulnerable Plaques: An Update.
Wang Y; Wang T; Luo Y; Jiao L
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139031
[TBL] [Abstract][Full Text] [Related]
9. Malnutrition-Inflammation Complex Syndrome and Bone Fractures and Cardiovascular Disease Events in Patients Undergoing Hemodialysis: The Q-Cohort Study.
Yamada S; Arase H; Yoshida H; Kitamura H; Tokumoto M; Taniguchi M; Hirakata H; Tsuruya K; Nakano T; Kitazono T
Kidney Med; 2022 Mar; 4(3):100408. PubMed ID: 35386605
[TBL] [Abstract][Full Text] [Related]
10. Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis - retrospective study.
Al Khayyat SG; Falsetti P; Conticini E; D'Alessandro R; Bellisai F; Gentileschi S; Baldi C; Bardelli M; Cantarini L; Frediani B
Reumatologia; 2021; 59(4):206-210. PubMed ID: 34538950
[TBL] [Abstract][Full Text] [Related]
11. Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).
Contenti J; Durand M; Vido S; Declemy S; Raffort J; Carboni J; Bonnet S; Koelsch C; Hassen-Khodja R; Gual P; Mazure NM; Sadaghianloo N
J Nephrol; 2022 Mar; 35(2):527-534. PubMed ID: 34468976
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?
Strobescu-Ciobanu C; Giuşcă SE; Căruntu ID; Amălinei C; Rusu A; Cojocaru E; Popa RF; Lupaşcu CD
Rom J Morphol Embryol; 2020; 61(3):793-801. PubMed ID: 33817720
[TBL] [Abstract][Full Text] [Related]
13. Plasma osteopontin as a biomarker of Alzheimer's disease and vascular cognitive impairment.
Chai YL; Chong JR; Raquib AR; Xu X; Hilal S; Venketasubramanian N; Tan BY; Kumar AP; Sethi G; Chen CP; Lai MKP
Sci Rep; 2021 Feb; 11(1):4010. PubMed ID: 33597603
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and mortality in end-stage renal disease patients.
Iseri K; Dai L; Chen Z; Qureshi AR; Brismar TB; Stenvinkel P; Lindholm B
Clin Kidney J; 2020 Jun; 13(3):307-321. PubMed ID: 32699616
[TBL] [Abstract][Full Text] [Related]
15. Plasma Osteoprotegerin Correlates with Stroke Severity and the Occurrence of Microembolic Signals in Patients with Acute Ischemic Stroke.
Cao Y; Cui C; Zhao H; Pan X; Li W; Wang K; Ma A
Dis Markers; 2019; 2019():3090364. PubMed ID: 31191747
[TBL] [Abstract][Full Text] [Related]
16. Deletion of Osteopontin Enhances β₂-Adrenergic Receptor-Dependent Anti-Fibrotic Signaling in Cardiomyocytes.
Pollard CM; Desimine VL; Wertz SL; Perez A; Parker BM; Maning J; McCrink KA; Shehadeh LA; Lymperopoulos A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897705
[TBL] [Abstract][Full Text] [Related]
17. Comparative Study of Protein Expression Levels of Five Plaque Biomarkers and Relation with Carotid Plaque Type Classification in Patients after Carotid Endarterectomy.
Kyriakidis K; Antoniadis P; Choksy S; Papi RM
Int J Vasc Med; 2018; 2018():4305781. PubMed ID: 30581625
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants.
Tschiderer L; Klingenschmid G; Nagrani R; Willeit J; Laukkanen JA; Schett G; Kiechl S; Willeit P
J Am Heart Assoc; 2018 Aug; 7(16):e009012. PubMed ID: 30369329
[TBL] [Abstract][Full Text] [Related]
19. Specific matrix metalloproteinases and calcification factors are associated with the vulnerability of human carotid plaque.
Guo ZY; Zhang B; Yan YH; Gao SS; Liu JJ; Xu L; Hui PJ
Exp Ther Med; 2018 Sep; 16(3):2071-2079. PubMed ID: 30186442
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
